NasdaqGS:NUVA

Stock Analysis Report

Executive Summary

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery.

Snowflake

Fundamentals

Moderate growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has NuVasive's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.3%

NasdaqGS:NUVA

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-8.5%

NasdaqGS:NUVA

8.7%

US Medical Equipment

1.7%

US Market

NUVA underperformed the Medical Equipment industry which returned 8.7% over the past year.

NUVA underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

NUVAIndustryMarket
7 Day4.3%-1.2%1.2%
30 Day1.9%1.4%4.9%
90 Day12.9%4.8%3.7%
1 Year-8.5%-8.5%9.6%8.7%3.9%1.7%
3 Year-1.7%-1.7%70.8%65.5%47.2%37.7%
5 Year76.6%76.6%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is NuVasive's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NuVasive undervalued based on future cash flows and its price relative to the stock market?

63.98x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

NuVasive's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

NuVasive's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

NuVasive is overvalued based on earnings compared to the US Medical Equipment industry average.

NuVasive is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

NuVasive is poor value based on expected growth next year.


Price Based on Value of Assets

NuVasive is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is NuVasive expected to perform in the next 1 to 3 years based on estimates from 18 analysts?

36.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

NuVasive's revenue is expected to grow by 5.5% yearly, however this is not considered high growth (20% yearly).

NuVasive's earnings are expected to grow significantly at over 20% yearly.

NuVasive's revenue growth is positive but not above the United States of America market average.

NuVasive's earnings growth is expected to exceed the United States of America market average.

NuVasive's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

NuVasive is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has NuVasive performed over the past 5 years?

17.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

NuVasive's year on year earnings growth rate has been positive over the past 5 years.

NuVasive's 1-year earnings growth exceeds its 5-year average (26.6% vs 17.5%)

NuVasive's earnings growth has not exceeded the US Medical Equipment industry average in the past year (26.6% vs 28.9%).


Return on Equity

NuVasive has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

NuVasive used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

NuVasive's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is NuVasive's financial position?


Financial Position Analysis

NuVasive is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

NuVasive's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

NuVasive's level of debt (71%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (53.6% vs 71% today).

Debt is well covered by operating cash flow (38.4%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 3.1x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.1x debt.


Next Steps

Dividend

What is NuVasive's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate NuVasive's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate NuVasive's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as NuVasive has not reported any payouts.

Unable to verify if NuVasive's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as NuVasive has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of NuVasive's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of NuVasive's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Chris Barry (46yo)

0.8yrs

Tenure

US$5,116,274

Compensation

Mr. J. Christopher Barry serves as CEO and Director of NuVasive, Inc. since November 5, 218. Mr. Barry served commercial and leadership roles at Covidien. He has extensive experience as an innovative globa ...


CEO Compensation Analysis

Chris's remuneration is about average for companies of similar size in United States of America.

Insufficient data for Chris to compare compensation growth.


Management Age and Tenure

1.7yrs

Average Tenure

44.5yo

Average Age

The average tenure for the NuVasive management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.6yrs

Average Tenure

57yo

Average Age

The tenure for the NuVasive board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Nathaniel Sisitsky (45yo)

    Senior VP

    • Tenure: 1.7yrs
  • Matt Link (44yo)

    President

    • Tenure: 0.7yrs
    • Compensation: US$2.85m
  • Frank Middeke

    Managing Director of DACH

    • Tenure: 5.8yrs
  • Rajesh Asarpota (52yo)

    Executive VP & CFO

    • Tenure: 2yrs
    • Compensation: US$1.57m
  • Suzanne Hatcher

    Vice President of Internal & External Affairs

    • Tenure: 0yrs
  • Johnson Lai

    Chief Information Officer

    • Tenure: 4.1yrs
  • Jereme Sylvain (39yo)

    Chief Accounting Officer

    • Tenure: 3.1yrs
  • Chris Barry (46yo)

    CEO & Director

    • Tenure: 0.8yrs
    • Compensation: US$5.12m
  • Lucas Vitale (43yo)

    Chief Human Resources Officer

    • Tenure: 0.7yrs
  • Jim Garrett

    Chief Compliance Officer

    • Tenure: 0.7yrs

Board Members

  • John DeFord (57yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$239.67k
  • Rob Friel (63yo)

    Director

    • Tenure: 3.6yrs
    • Compensation: US$228.76k
  • Vickie Capps (57yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$238.76k
  • Greg Lucier (55yo)

    Chairman of the Board

    • Tenure: 4.5yrs
    • Compensation: US$4.63m
  • Dan Wolterman (62yo)

    Director

    • Tenure: 4.2yrs
    • Compensation: US$248.76k
  • Don Rosenberg (68yo)

    Lead Director

    • Tenure: 1.3yrs
    • Compensation: US$241.26k
  • Leslie Norwalk (54yo)

    Director

    • Tenure: 5.3yrs
    • Compensation: US$233.76k
  • R. Huennekens (54yo)

    Director

    • Tenure: 0.9yrs
    • Compensation: US$114.41k
  • Chris Barry (46yo)

    CEO & Director

    • Tenure: 0.8yrs
    • Compensation: US$5.12m

Company Information

NuVasive, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NuVasive, Inc.
  • Ticker: NUVA
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$3.380b
  • Shares outstanding: 52.05m
  • Website: https://www.nuvasive.com

Number of Employees


Location

  • NuVasive, Inc.
  • 7475 Lusk Boulevard
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NUVANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2004
NK8DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2004
NUVA *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 2004

Biography

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine f ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:40
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.